Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

On July 29, 2022 Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) reported that it will host a conference call at 8:00 a.m. ET Friday, August 5, 2022 to report financial results for the quarter ended June 30, 2022 and discuss recent corporate highlights (Press release, Aldeyra Therapeutics, JUL 29, 2022, View Source [SID1234617148]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in numbers are (844) 200-6205 for domestic callers and (929) 526-1599 for international callers. The access code is 908644. A live audio webcast of the conference call also will be accessible from the "Investors & Media" section of Aldeyra’s website at View Source

After the live webcast, the event will remain archived on Aldeyra’s website for 90 days.

New NSF awards will advance theoretical foundations of data science research through interdisciplinary collaborations

On July 29, 2022 National Science Foundation reported that Data science is an expanding field that requires the expertise of computer scientists, engineers, mathematicians, and statisticians to handle the complex analysis of ever-larger data sets (Press release, National Science Foundation, JUL 29, 2022, View Source [SID1234617130]). Data affect how industry, academia and government operate. The U.S. National Science Foundation is committed to leading the nation in foundational data science research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of this effort, NSF announces two new Transdisciplinary Research in Principles of Data Science, or TRIPODS, Phase II awards totaling $20 million that bring together scientists and engineers from different research communities to further the theoretical foundations of data science through integrated research and training activities. TRIPODS is tied to NSF’s Harnessing the Data Revolution Big Idea, which aims to accelerate discovery and innovation in data science algorithms, data infrastructure, and education and workforce development.

Phase II of the program will continue to support the development of collaborative institutes to delve deeper into foundational issues in data science, such as design of algorithms for analyzing large, complex, noisy and changing data sets; data that includes historical biases and elements influenced by self-interested and possibly malicious parties; and the need for fair, ethical and understandable results from complex data-driven decision-making processes.

"The NSF TRIPODS Institutes will bring advances in data science theory that improve health care, manufacturing, and many other applications and industries that use data for decision-making," said NSF Division Director for Electrical, Communications and Cyber Systems Shekhar Bhansali.

TRIPODS awards aim to achieve these goals and other long-term major impacts in areas ranging from basic science to commerce and law by bringing together electrical engineering, mathematics, statistics, and theoretical computer science communities in synergistic and mutually beneficial ways to develop a unified foundation for data science.

NSF is supporting two new teams over five years focused on these topics, bringing the total number of TRIPODS Phase II Institutes to four. Previous TRIPODS Institutes were announced in 2020.

The Institute for Emerging CORE Methods in Data Science, or EnCORE, is led by the University of California San Diego in collaboration with the University of California, Los Angeles; University of Pennsylvania; and The University of Texas at Austin. EnCORE brings together scientists from multiple disciplines such as statistics, mathematics, electrical engineering, theoretical computer science, machine learning and health science, among others.

EnCORE’s team will focus on the four CORE pillars of data science: C for complexities of data, O for optimization, R for responsible learning, and E for education and engagement. The institute is fostering a plan for outreach and broadening participation by engaging students of diverse backgrounds at all levels, from K-12 to postdocs and junior faculty. The project aims to reach a wide demography of students by offering collaborative courses across its partner universities and a flexible co-mentorship plan for multidisciplinary research.

To bring theoretical development into practice, EnCORE will work with industry partners and domain scientists and will forge strong connections with other NSF Harnessing the Data Revolution Institutes across the nation.

Institute for Emerging CORE Methods in Data Science awards: UC San Diego, UCLA, University of Pennsylvania, and The University of Texas at Austin.

The Institute for Data, Econometrics, Algorithms, and Learning, or IDEAL, is a multi-institution and transdisciplinary institute led by the University of Illinois Chicago in collaboration with Northwestern University; Toyota Technological Institute at Chicago; the University of Chicago; and Illinois Institute of Technology, in partnership with members of the Learning Theory team at Google. The institute involves more than 50 researchers working on key aspects of the foundations of data science across computer science, electrical engineering, mathematics, statistics, and fields such as economics, operations research and law.

Research will center around the foundations of machine learning, high-dimensional data analysis and inference, and data science and society. Topics include foundations of deep learning, reinforcement learning, machine learning and logic, network inference, high-dimensional data analysis, trustworthiness and reliability, fairness, and data science with strategic agents.

The institute will broaden research and education participation from underrepresented groups by organizing activities that engage diverse communities of students at all levels, including high school and undergraduate students, as well as teachers (through a partnership with Math Circles of Chicago) and the public (via lectures in partnership with the Museum of Science and Industry).

Institute for Data, Econometrics, Algorithms, and Learning awards: UIC, Toyota Technological Institute, The University of Chicago, IIT, Northwestern University.

"The new 2022 TRIPODS awards address foundational challenges in data science at the core of data-driven discovery and decision making," said NSF Division Director for Computing and Communication Foundations (CCF) Dilma Da Silva. "CCF is pleased to be able to support these impactful projects."

VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock

On July 29, 2022 VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, reported the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share (Press release, VolitionRX, JUL 29, 2022, View Source [SID1234617149]). The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million. In addition, Volition has granted the underwriter in the offering a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the offering. The offering is expected to close on or about August 2, 2022, subject to the satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corporate purposes, including potential strategic acquisitions.

Newbridge Securities Corporation is acting as the sole book-running manager of the offering.

The securities are being offered by Volition pursuant to a "shelf" registration statement on Form S-3 (File No. 333-259783) previously filed with the Securities and Exchange Commission (the "SEC") on September 24, 2021 and declared effective by the SEC on November 8, 2021. The offering is being made only by means of a prospectus supplement and an accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that the Company may file with the SEC. A preliminary prospectus supplement and an accompanying base prospectus describing the terms of the proposed offering have been filed with the SEC and are available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering can also be obtained, when available, from Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, FL 33432, by email at [email protected], or by telephone at (877) 447-9625. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Anaveon to present new data from the Phase I/II study of ANV419 at the ESMO Congress 2022

On July 29, 2022 Anaveon reported that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, in a poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, taking place in Paris, September 9 – 13, 2022 (Press release, Anaveon, JUL 29, 2022, View Source [SID1234617132]). Abstracts will be available online starting 00.05 CEST on Monday, September 5, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the poster presentations are:

Abstract Title: "ANV419, a selective IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, in patients with advanced solid tumors, a phase I/II study"

Presentation Number: 479P
Location: Poster Area Hall 4

Authors: H. Läubli, G. Alonso, J. Lopez, E. Calvo, M. Jörger, V. Sanchez, D. Di Blasi, A. Nair, K. Richter, Ch Huber, J Mouton, S. Costanzo, S. Jethwa, Ch Bucher and E. Garralda
Date/Time: 12 September 2022 at 9:00 CEST – 18:30 CEST

Abstract Title: "ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity"

Presentation Number: 39P
Location: Poster Area Hall 4

Authors: K. Richter, N. Egli, L. Petersen, P. Murer, A. Katopodis and Ch. Huber
Date/Time: 11 September 2022 at 9:00 CEST – 18:30 CEST

Please visit the ESMO (Free ESMO Whitepaper) website here for more information.

Anaveon is undertaking a Phase I/II study to evaluate the safety, dosing and clinical activity of its lead program, ANV419, a powerful and selective interleukin-2 (IL-2) agonist in patients with solid tumors. The Company is pursuing multiple parallel Phase II programs in order to explore the full therapeutic potential of ANV419. In addition, Anaveon continues its work in developing follow-on compounds to expand on the success of ANV419 by delivering the IL-2 agonist to tumor fighting cells and thus expand the therapeutic potential into less immunogenic tumors. Alongside this, the Company is building on its cytokine engineering expertise with preclinical-stage programs harnessing the power of cytokines for therapeutic purposes.

HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update

On July 29, 2022 HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company focusing on delivering breakthrough therapies for patients, reported financial results for the second quarter 2022 as well as an update to its R&D progress (Press release, HanAll Biopharma, JUL 29, 2022, View Source [SID1234617150]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The second quarter delivered strong momentum for HanAll Biopharma. Our operating income has turned to profit while we continued our investment in R&D" said Sean Jeong, M.D., CEO of HanAll Biopharma.

"Moving forward over the next few quarters, we expect to see topline results for the Phase 3 study in dry eye disease in the US, while enhancing our portfolio through open collaborations. HanAll will continue to invest in R&D to bring innovative therapeutics to patients" he added.

SECOND QUARTER 2022 BUSINESS UPDATE
Pipeline Development Highlights

A comprehensive update on HanAll’s pipeline development includes an overview of HanAll’s research and a list of compounds in development with targeted indication and the phase of development.

Batoclimab (Project Code: HL161)

A novel, fully human, anti-FcRn antibody being developed as a subcutaneous injection for the treatment of rare autoimmune diseases mediated by pathogenic IgG antibodies.

In March 2022, Harbour BioMed, a licensed partner of HanAll updated full clinical development progress in batoclimab. The company is progressing towards Biologics License Application (BLA) submission in the calendar year of 2022, after obtaining topline results from Phase 3 clinical trial for myasthenia gravis (MG). Harbour is developing batoclimab in a wide range of autoimmune indications in addition to MG, including immune thrombocytopenic purpura (ITP), neuromyelitis optica spectrum disorder (NMOSD) and thyroid eye disease (TED).
In June 2022, Immunovant, a global licensed partner of HanAll initiated a Phase 3 study to further evaluate the efficacy of batoclimab in MG. Immunovant expects to reveal two new indication programs by August 2022.
HanAll Biopharma plans to initiate a Phase 3 clinical trial in MG in collaboration with Immunovant in Japan, during the 2H 2022.
Tanfanercept (Project Code: HL036)

A novel, topical anti-TNF alpha biologic therapy for dry eye disease (DED) which aims to treat inflammatory eye diseases by inhibiting TNF alpha, which is critical in ocular inflammation.

HanAll Biopharma and Daewoong Pharmaceutical are continuing to conduct their second Phase 3 clinical study (Study name: VELOS-3) in DED to examine the safety and efficacy of the medication, at nine clinical sites located in the U.S. The study design was recently expanded to include a pharmacogenomics component that could deliver more value for patients and prescribers from this study.
Harbour BioMed is conducting its pivotal Phase 3 trial on tanfanercept in patients with DED.
HL187/ HL186

HanAll is advancing its development in immuno-oncology therapeutics, that respectively target TIM-3 and TIGIT with Daewoong Pharmaceutical.

HL187 is in pre-clinical development and antibody screening is ongoing to select the lead molecule in HL186.
Major Development Highlights

HanAll further advanced its partnerships with companies with promising technologies.

HanAll supported Neudive, a company developing digital therapeutic solutions to help neurodiverse children. Neudive’s platform is expected to deliver individually tailored therapy programs to children with neurodevelopmental disorders by using VR technology.
FINANCIAL HIGHLIGHTS (PROVISIONAL)
Key Highlights

Sales were 26.2 billion won in the second quarter, a 12% increase compared to the same period last year. Sales growth was mainly driven by continued strong performance from pharmaceuticals sold under the names of Normix, Eligard, Biotop and other major products.
R&D expenses showed 45.1 % increase compared to the same period last year, recording around 3.6 billion won.
Operating income was 682 million won, a 56.6% decrease, compared to the same period last year, mainly due to increased investment in R&D.